Oppenheimer Maintains Pennant Group(PNTG.US) With Buy Rating, Maintains Target Price $37
Truist Financial Maintains Pennant Group(PNTG.US) With Hold Rating, Announces Target Price $38
Pennant Group Is Maintained at Outperform by Oppenheimer
Pennant Gr Analyst Ratings
Oppenheimer Maintains Pennant Group(PNTG.US) With Buy Rating, Raises Target Price to $37
RBC Capital Maintains Pennant Group(PNTG.US) With Buy Rating, Maintains Target Price $38
Truist Financial Maintains Pennant Group(PNTG.US) With Hold Rating
RBC Capital Maintains Pennant Group(PNTG.US) With Buy Rating, Raises Target Price to $38
RBC Capital Sticks to Their Buy Rating for Pennant Group (PNTG)
Pennant Gr Analyst Ratings
Stephens Maintains Pennant Group(PNTG.US) With Buy Rating, Raises Target Price to $40
Pennant Group Is Maintained at Hold by Truist Securities
Pennant Gr Analyst Ratings
Truist Financial Maintains Pennant Group(PNTG.US) With Hold Rating, Announces Target Price $38
Pennant Gr Analyst Ratings
Truist Financial Maintains Pennant Group(PNTG.US) With Hold Rating
Truist Securities Adjusts Price Target on Pennant Group to $34 From $28, Maintains Hold Rating
Pennant Group Price Target Raised to $32.00/Share From $28.00 by Stephens & Co.
Pennant Gr Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pennant Group (PNTG), Merus (MRUS) and Sangamo Biosciences (SGMO)